Annovis Bio Inc. (NYSE: ANVS)

Introduction

Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its lead compound, buntanetap, is a small, once-daily, orally administered inhibitor of multiple neurotoxic proteins, designed to restore nerve-cell function and address cognitive and motor decline.

Corporate Structure

• Founded: 2008
• Headquarters: Malvern, Pennsylvania
• Employees: Approximately 10 (LinkedIn estimate)
• Significant Shareholders (as of 2025-03-31):
  • CVI Investments, Inc.: 1,000,000 shares (4.9%)
  • Heights Capital Management, Inc.: 1,000,000 shares (4.9%)

Recent Developments and News

• February 3, 2025: Annovis priced an underwritten public offering of 5,250,000 common shares and warrants at $4.00 per unit, expected to close on February 4. Gross proceeds: $21 million. Proceeds allocated for working capital and continued clinical development.
• March 21, 2025: Q4 and full-year 2024 financial results released:
  • Q4 R&D expenses decreased to $5.0 million from $8.9 million (Q4 2023)
  • Q4 net loss per share improved to $0.43 from $2.24
  • FY 2024 R&D expenses: $20.0 million compared to $38.8 million (2023)
  • Cash and equivalents: $10.6 million as of December 31, 2024; post-offering shares outstanding: 19.5 million
• March 25, 2025: Participation at the AD/PD™ 2025 conference in Vienna to present Phase 3 PD and Phase 2/3 AD data focusing on cognition, motor function, and responses from APOE4 carriers.
• March 27, 2025: Received a continued listing standard notice from the NYSE due to average market capitalization ($37.9 million) and stockholders’ equity ($9.3 million) falling below the $50 million thresholds. A compliance plan is due within 45 days, with an 18-month cure period.
• Early 2025: Initiation of pivotal Phase 3 AD trial; symptomatic data readout anticipated mid-2026, with disease-modifying data expected in mid-2027.

Financial and Strategic Analysis

Metric	Value
Share price (2025-05-28)	$2.41
Intraday change	+18.14%
52-week range	$1.11 – $17.88
Volume (2025-05-28)	480,975
Avg. daily volume	354,568
Market cap (intraday)	$46.96 million
Cash & equivalents (mrq)	$22.24 million
Q4 2024 R&D expenses	$5.0 million
Q4 2024 net loss per share	$0.43
FY 2024 R&D expenses	$20.0 million
FY 2024 G&A expenses	$6.7 million
Shares outstanding (post-offering)	19.5 million
Cash runway	Into Q4 2025 (estimate)

• Cost Management: R&D spending declined by 44% in Q4 2024 compared to Q4 2023, indicating operational efficiencies.
• Capital Raise & Dilution: The $21 million capital raise in February 2025 extended the cash runway into late 2025 but increased the share count by approximately 38% (from 14.1 million to 19.5 million).
• Liquidity & Listing Risk: With cash balances around $22 million (mrq) and the NYSE notice received, executing the compliance plan and securing additional capital are critical for continuing operations.
• Clinical Investment: The strategic focus on the Phase 3 AD trial—with a two-stage design of 6-month symptomatic and 18-month disease-modifying assessments—aligns with regulatory pathways towards potential New Drug Applications (NDAs) planned for 2027.

Market Position and Industry Context

• Therapeutic Differentiation: Buntanetap’s mechanism targeting multiple neurotoxic proteins (APP, tau, α-synuclein) distinguishes it from traditional single-target therapies, including anti-amyloid antibodies.
• Competitive Landscape: Annovis competes with established AD drugs (e.g., lecanemab) and PD treatments but aims to address both cognitive and motor function in dual indications with limited competition.
• Clinical Validation: Initial results highlight improvements in Phase 3 PD (MDS-UPDRS enhancement and halted cognitive decline) and Phase 2/3 AD (ADAS-Cog11 gains, response in APOE4 carriers), reinforcing the clinical strategy aimed at early intervention.
• Scientific Engagement: Active participation in scientific forums (CTAD, AD/PD™ 2025) and the generation of peer-reviewed publications enhance visibility and engagement among regulatory authorities and investors.

tl;dr

• ANVS shares traded at $2.41 (+18.14%) on May 28, 2025, with increased trading volume.
• Completed a $21 million financing on February 4, 2025; cash runway extended into Q4 2025.
• Initiated a pivotal Phase 3 Alzheimer’s trial in early 2025; symptomatic readout expected mid-2026, with disease-modifying data anticipated in mid-2027.
• Received NYSE notice on March 27, 2025, regarding listing standards; a compliance plan is required within 45 days.
• Q4 2024 results reported a net loss of $0.43/share with reduced R&D expenditure, reflecting streamlined operations ahead of significant data milestones.